These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22824305)

  • 1. Long-term nerve excitability changes by persistent Na+ current blocker ranolazine.
    Nodera H; Rutkove SB
    Neurosci Lett; 2012 Aug; 524(2):101-6. PubMed ID: 22824305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of the peripheral nerve excitability in vivo induced by the persistent Na+ current blocker ranolazine.
    Nodera H; Rutkove SB
    Neurosci Lett; 2012 Jun; 518(1):36-40. PubMed ID: 22575609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine.
    Hirakawa R; El-Bizri N; Shryock JC; Belardinelli L; Rajamani S
    Neuropharmacology; 2012 Jun; 62(7):2251-60. PubMed ID: 22313527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Na(+) channel expression and nodal persistent Na(+) currents associated with peripheral nerve regeneration in mice.
    Nakata M; Baba H; Kanai K; Hoshi T; Sawai S; Hattori T; Kuwabara S
    Muscle Nerve; 2008 Jun; 37(6):721-30. PubMed ID: 18506710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability.
    Kiernan MC; Krishnan AV; Lin CS; Burke D; Berkovic SF
    Brain; 2005 Aug; 128(Pt 8):1841-6. PubMed ID: 15857929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels.
    Kahlig KM; Hirakawa R; Liu L; George AL; Belardinelli L; Rajamani S
    Mol Pharmacol; 2014 Jan; 85(1):162-74. PubMed ID: 24202911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.
    Kahlig KM; Lepist I; Leung K; Rajamani S; George AL
    Br J Pharmacol; 2010 Nov; 161(6):1414-26. PubMed ID: 20735403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction.
    Wu Y; Song Y; Belardinelli L; Shryock JC
    J Pharmacol Exp Ther; 2009 Aug; 330(2):550-7. PubMed ID: 19403851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninactivating, tetrodotoxin-sensitive Na+ conductance in peripheral axons.
    Tokuno HA; Kocsis JD; Waxman SG
    Muscle Nerve; 2003 Aug; 28(2):212-7. PubMed ID: 12872326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine inhibits shear sensitivity of endogenous Na+ current and spontaneous action potentials in HL-1 cells.
    Strege P; Beyder A; Bernard C; Crespo-Diaz R; Behfar A; Terzic A; Ackerman M; Farrugia G
    Channels (Austin); 2012; 6(6):457-62. PubMed ID: 23018927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and pharmacology of the cardiac "late sodium current.".
    Zaza A; Belardinelli L; Shryock JC
    Pharmacol Ther; 2008 Sep; 119(3):326-39. PubMed ID: 18662720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
    Estacion M; Waxman SG; Dib-Hajj SD
    Mol Pain; 2010 Jun; 6():35. PubMed ID: 20529343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells.
    Chen BS; Lo YC; Peng H; Hsu TI; Wu SN
    J Pharmacol Sci; 2009 Jul; 110(3):295-305. PubMed ID: 19609066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple measures of axonal excitability in peripheral sensory nerves: an in vivo rat model.
    George A; Bostock H
    Muscle Nerve; 2007 Nov; 36(5):628-36. PubMed ID: 17654556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical studies of rapidly inactivating and noninactivating sodium currents in differentiated NG108-15 neuronal cells.
    Wu SN; Chen BS; Hsu TI; Peng H; Wu YH; Lo YC
    J Theor Biol; 2009 Aug; 259(4):828-36. PubMed ID: 19446569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of mexiletine on excitability properties of human median motor axons.
    Kuwabara S; Misawa S; Tamura N; Kanai K; Hiraga A; Ogawara K; Nakata M; Hattori T
    Clin Neurophysiol; 2005 Feb; 116(2):284-9. PubMed ID: 15661106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine vs phenytoin: greater effect of ranolazine on the transient Na(+) current than on the persistent Na(+) current in central neurons.
    Terragni B; Scalmani P; Colombo E; Franceschetti S; Mantegazza M
    Neuropharmacology; 2016 Nov; 110(Pt A):223-236. PubMed ID: 27450092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Na+ channels ameliorates arrhythmias in a drug-induced model of Andersen-Tawil syndrome.
    Radwański PB; Greer-Short A; Poelzing S
    Heart Rhythm; 2013 Feb; 10(2):255-63. PubMed ID: 23041575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish.
    Kiernan MC; Isbister GK; Lin CS; Burke D; Bostock H
    Ann Neurol; 2005 Mar; 57(3):339-48. PubMed ID: 15732107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine, an inhibitor of the late sodium channel current, reduces postischemic myocardial dysfunction in the rabbit.
    Hale SL; Kloner RA
    J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):249-55. PubMed ID: 17220471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.